Avodart Cost in Delaware 2026: Dutasteride Prices, Insurance, and Savings

What Does Avodart Cost in Delaware in 2026?

Generic dutasteride 0.5 mg costs around $25 per month at Delaware retail pharmacies when purchased cash-pay, while the Avodart brand name carries a list price near $290 per month. The price gap between brand and generic is large enough that almost every cost-conscious patient in Delaware should start with a generic. GoodRx and similar discount platforms often bring the generic below $20 at chains such as Walmart, Costco, and CVS in Wilmington and Dover.

Dutasteride is a dual 5-alpha-reductase inhibitor (5-ARI) that suppresses both type I and type II 5-alpha-reductase enzymes, reducing dihydrotestosterone (DHT) by roughly 90% within two weeks of starting therapy [1]. The FDA approved dutasteride (Avodart) for BPH in November 2001 [2]. Finasteride, the competing 5-ARI, inhibits only type II, producing a smaller DHT reduction of approximately 70% [3].

Because the active pharmaceutical ingredient is off-patent and widely manufactured, retail competition among Delaware pharmacies keeps generic prices low. Patients paying out-of-pocket should always use a discount card at checkout; cash price without any card at an independent Delaware pharmacy averages closer to $60 to $80 per month, so the discount-card price of $25 represents a meaningful reduction.

Delaware has 49 retail pharmacy locations across New Castle, Kent, and Sussex counties as of 2025. Filling a 90-day supply rather than a 30-day supply typically lowers the per-unit cost by an additional 10 to 15 percent at mail-order pharmacies.

How Delaware Medicaid Covers Dutasteride

Delaware Medicaid (Diamond State Health Plan and Diamond State Health Plan Plus) covers generic dutasteride for BPH with a prior authorization (PA) requirement. The PA process asks the prescriber to document a diagnosis of symptomatic BPH, usually with an International Prostate Symptom Score (IPSS) of 8 or higher, and to confirm that an alpha-blocker trial of at least four weeks was attempted or is contraindicated [4].

Off-label use of dutasteride for androgenetic alopecia is generally not covered under Delaware Medicaid without a specific medical necessity appeal. Providers using telehealth platforms to treat Delaware Medicaid patients must bill through a Delaware-credentialed provider and follow the Division of Medicaid and Medical Assistance (DMMA) telehealth billing rules updated in 2023.

Once PA is granted, the patient cost-share under Delaware Medicaid is a nominal copay, typically $1 to $3 per fill for a generic drug at preferred-tier status. That makes dutasteride one of the most affordable BPH medications available to low-income Delaware residents who qualify. The DMMA preferred drug list is updated quarterly, so prescribers should verify current PA criteria at the Delaware DMMA portal before submitting [5].

Patients enrolled in a Medicare Part D plan through one of Delaware's 24 Part D contracts (plan year 2026) will typically find generic dutasteride on Tier 2 or Tier 3, with copays ranging from $10 to $47 per month depending on whether they have reached the deductible phase. The Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap, effective January 2025, benefits Delaware Medicare patients on multi-drug regimens that include dutasteride [6].

Which Private Insurance Plans Cover Avodart in Delaware?

Most commercial insurance plans operating in Delaware cover generic dutasteride on their formulary; brand-name Avodart is usually on a non-preferred or specialty tier. The three largest commercial insurers in Delaware by individual market enrollment are Highmark Blue Cross Blue Shield of Delaware, Aetna, and UnitedHealthcare, all of which list generic dutasteride on their 2026 formularies at Tier 2 (preferred generic), with typical copays of $10 to $20 per month after the deductible.

A step-therapy requirement is common: the plan may require documentation that the patient tried an alpha-blocker such as tamsulosin 0.4 mg for 30 days before approving dutasteride. Employers using a self-insured plan governed by ERISA may have different formulary rules; employees at large Delaware employers such as DuPont, ChristianaCare, and Sallie Mae should check their Summary of Benefits and Coverage documents directly.

The GSK manufacturer savings card for Avodart brand-name is available to commercially insured patients and can reduce out-of-pocket cost to as low as $30 per month for eligible patients. It is not valid for federal or state government-funded plans including Delaware Medicaid or Medicare Part D, per GSK program terms [7]. Given that generic dutasteride already costs $25 cash-pay, the savings card is most useful for patients whose commercial plan places brand-name Avodart at a lower tier than the generic for any formulary-specific reason.

Is Compounded Dutasteride Legal in Delaware?

Compounded dutasteride is legal in Delaware when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare customized preparations for individual patients [8]. Delaware's Board of Pharmacy enforces state-level compliance with USP Chapter 795 (non-sterile compounding) standards for oral capsule formulations of dutasteride.

503B outsourcing facilities, which produce large-volume compounded drugs without a patient-specific prescription, do not legally compound dutasteride because it is an FDA-approved commercially available drug not on the FDA 503B drug shortage list. The legal pathway in Delaware is exclusively through a licensed 503A pharmacy with a prescription in hand.

Compounded dutasteride in Delaware averages approximately $40 per month in 2026. That price is higher than the $25 generic cash-pay price, which leads to an important clinical question: why would a patient choose compounded? Compounded formulations offer customizable doses (for example, lower doses such as 0.1 mg or 0.25 mg used off-label in hair-loss protocols) or combination capsules pairing dutasteride with minoxidil or other actives that are not commercially available as a single product [9].

The HealthRX prescribing team uses a three-tier decision framework when evaluating dutasteride sourcing for Delaware patients:

1. Generic 0.5 mg at retail pharmacy for BPH or standard-dose alopecia treatment.
2. Compounded 503A preparation for patients requiring non-standard doses or combination formulations.
3. Brand-name Avodart only when a manufacturer savings program or formulary quirk makes it cost-neutral.

This framework reduces unnecessary compounding spend while preserving access to customized therapy when the clinical situation calls for it.

Clinical Evidence Supporting Dutasteride Use

Dutasteride's BPH efficacy is established by the COMBAT trial (N=1,630), a four-year randomized controlled study showing that the dutasteride-tamsulosin combination reduced the relative risk of acute urinary retention or BPH-related surgery by 66% compared with tamsulosin monotherapy (P<0.001) [10]. The American Urological Association 2021 guidelines cite dutasteride 0.5 mg once daily as an appropriate medical therapy for men with moderate-to-severe LUTS secondary to BPH and prostate volume greater than 30 mL [11].

For androgenetic alopecia, Eun et al. (J Am Acad Dermatol 2010, N=153) found that dutasteride 0.5 mg daily produced significantly greater increases in total hair count at 24 weeks compared with finasteride 1 mg daily (P<0.05), with a mean hair-count increase of 12.2 hairs per cm squared versus 7.3 hairs per cm squared [12]. Off-label use in hair loss is not FDA-approved but is increasingly supported by the literature and is practiced widely across telehealth platforms in Delaware and other states.

The REDUCE trial (N=8,231), a four-year study examining dutasteride 0.5 mg in men at elevated risk for prostate cancer, showed a 23% relative risk reduction in prostate cancer diagnosis versus placebo over the study period [13]. The FDA has not approved dutasteride for prostate cancer prevention, and the label carries a warning about a possible increase in high-grade prostate cancer. Prescribers in Delaware should document this risk discussion in the medical record.

Serum DHT suppression reaches approximately 90% by week two of therapy, with maximal PSA reduction of around 50% occurring at six months. That PSA halving effect means any PSA value obtained after six or more months of dutasteride should be doubled to estimate a pre-treatment equivalent, per AUA guidance [11].

Telehealth Access to Dutasteride in Delaware

Telehealth prescribing of dutasteride is legal in Delaware as of 2026. Delaware's telemedicine statute (Title 24, Delaware Code) permits licensed physicians and advanced practice providers to prescribe Schedule-exempt medications including dutasteride via synchronous audiovisual visits. Asynchronous (store-and-forward) prescribing is permitted for established patients under Delaware Board of Medicine regulations updated in 2022.

A Delaware-licensed prescriber does not need to examine the patient in person before initiating dutasteride therapy, provided a clinically adequate medical history, symptom assessment (IPSS for BPH or standardized hair-loss grading for alopecia), and relevant labs (PSA, comprehensive metabolic panel) have been reviewed. HealthRX providers complete this intake through a HIPAA-compliant asynchronous intake form followed by a synchronous visit when clinically indicated [14].

Patients outside major Delaware population centers (such as those in rural Sussex County) benefit most from telehealth prescribing because travel to a urologist or dermatologist can involve round-trip distances exceeding 60 miles. Telehealth platforms that are not licensed in Delaware cannot legally prescribe to Delaware residents, so patients should confirm their provider holds a Delaware license before subscribing.

Practical Savings Strategies for Delaware Patients

Generic dutasteride at $25 per month is already low-cost, but several additional strategies can reduce expenditure further or remove it entirely for qualifying patients.

GoodRx, RxSaver, and NeedyMeds discount cards are free to obtain and accepted at most Delaware retail pharmacies. Presenting a discount card instead of insurance is sometimes cheaper for patients whose commercial plan has a high deductible, because generic dutasteride often costs less than a standard insurance copay during the deductible phase.

NeedyMeds and the Partnership for Prescription Assistance list patient assistance programs (PAPs) for brand-name Avodart for uninsured or underinsured Delaware residents with household income below 400% of the federal poverty level [15]. GSK's patient assistance program can provide Avodart at no cost for qualifying patients; applications are submitted by the prescriber on the patient's behalf.

The Delaware Prescription Assistance Program (DPAP), administered by the Delaware Department of Health and Social Services, helps residents aged 18 and older who do not qualify for Medicaid but have household income up to 200% of the federal poverty level. DPAP supplements Medicare Part D coverage and may offset copay costs for dutasteride when the drug is on the plan formulary [16].

Buying a 90-day supply via mail order through Express Scripts, CVS Caremark, or OptumRx typically reduces per-dose cost compared with 30-day retail fills. For patients paying cash, Costco Pharmacy in Christiana, Delaware charges among the lowest out-of-pocket rates for generic dutasteride in the state; no Costco membership is required to use the pharmacy.

Dosing, Safety, and Monitoring for Delaware Prescribers

The FDA-approved dose for BPH is dutasteride 0.5 mg once daily by mouth, with or without food. Capsules must be swallowed whole because dutasteride is a skin and mucous-membrane irritant in liquid form [2]. Women who are pregnant or may become pregnant must not handle crushed or leaking capsules due to risk of fetal harm from 5-ARI exposure.

Off-label hair-loss dosing in clinical practice ranges from 0.1 mg to 0.5 mg daily. Some hair-loss protocols use 0.5 mg once daily; others use 0.5 mg once weekly or 2.5 mg once weekly, though evidence for weekly regimens is limited to small studies [17]. The compounded route allows these non-standard doses.

Baseline PSA should be measured before starting therapy. The AUA recommends PSA monitoring at six months to establish the new on-treatment baseline, then at 12-month intervals thereafter [11]. A rise in PSA while on dutasteride warrants evaluation for prostate cancer regardless of the absolute value. Sexual side effects including decreased libido, erectile dysfunction, and ejaculatory disorders occur in approximately 5 to 10% of patients in clinical trials and are generally reversible on discontinuation [10].

Drug interactions are limited but worth noting: dutasteride is metabolized by CYP3A4 and CYP3A5. Co-administration with strong CYP3A4 inhibitors such as ritonavir or ketoconazole may increase dutasteride plasma concentrations. Verapamil and diltiazem are moderate inhibitors and may modestly raise dutasteride levels; clinical monitoring is appropriate but dose adjustment is rarely needed.

Dutasteride has a very long half-life of approximately five weeks, meaning drug concentrations persist for several months after discontinuation. Patients who donate blood should not do so for at least six months after the last dose because dutasteride in donated blood could harm a pregnant recipient [2].

How HealthRX Manages Dutasteride Prescribing in Delaware

HealthRX is licensed to prescribe in Delaware. Our intake process collects a completed IPSS questionnaire or standardized hair-loss severity scale, a self-reported medication and allergy list, and PSA lab results (for male patients over 40) before a Delaware-licensed provider reviews the case. Prescriptions are sent electronically to the pharmacy of the patient's choice, including 503A compounding pharmacies for patients requiring non-standard formulations.

Patients seeking the $25 generic will be directed to a local retail pharmacy with a pre-loaded discount code. Patients needing compounded dutasteride will receive a prescription sent to our partner 503A pharmacy. Follow-up messaging via the HealthRX portal at 30, 90, and 180 days captures symptom changes and any side-effect reports, with a synchronous visit triggered if PSA rises or side effects are significant.

As the American Urological Association 2021 guideline states: "Combination therapy with an alpha-blocker and a 5-alpha-reductase inhibitor is more effective than either agent alone in men with LUTS/BPH with an enlarged prostate" [11]. For Delaware patients being managed primarily for BPH who are already on tamsulosin or alfuzosin, adding dutasteride through HealthRX follows that guideline recommendation directly. For hair-loss patients, the prescriber documents the off-label rationale, discusses the risk-benefit profile, and obtains informed consent before the first prescription is sent.